# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Pre-Negotiated, Expedited Restructuring Expected to Substantially Reduce Debt and Optimize Liquidity Party City Stores Open, S...
Gainers Celyad Oncology SA (NASDAQ: CYAD) rose 221.7% to $2.57 in pre-market trading after gaining 21% on Friday. Celyad Onc...